China SXT Pharmaceuticals, Inc. has announced a registered direct offering worth $12 million. The offering consists of Class A ordinary shares and warrants, aimed at strengthening the company's financial position. This move is significant as it highlights the company's efforts to attract institutional investors and secure funding for future growth.
On October 8, 2026, the company disclosed that it entered into a definitive agreement with certain institutional investors for the purchase and sale of 8,000,000 Class A ordinary shares at a purchase price of $1.50 per share. Additionally, the company will issue 8,000,000 warrants with an exercise price of $2.75 per share. The warrants are immediately exercisable and have a one-year term.
The gross proceeds from this offering are expected to be approximately $12 million before deducting fees and expenses. Investors also have the option to acquire up to an additional $12 million of securities under similar terms within a 30-day period after the closing of the offering.
China SXT Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the research, development, manufacture, and marketing of traditional Chinese medicine. The company is listed on the Nasdaq under the ticker SXTC.
The offering is anticipated to close on or about October 9, 2026, subject to customary closing conditions. Univest Securities, LLC is acting as the sole placement agent for this offering.
This announcement comes at a time when the pharmaceutical industry is witnessing increased investor interest, particularly in companies that are innovating within the sector. The funds raised from this offering will likely support China SXT Pharmaceuticals' ongoing projects and expansion efforts.
Details regarding the use of proceeds from the offering were not disclosed in the filing. However, the company has emphasized its commitment to advancing its business strategy and enhancing shareholder value.
For more information, the company has provided a press release which is incorporated into the filing as Exhibit 99.1. This document outlines the terms of the offering and provides further insights into the company's operational focus.